Windward Bio

Switzerland
Breíl, Grisons, Switzerland

Company profile

Windward Bio company profile

Windward Bio is a clinical-stage drug development company focused on improving outcomes for individuals with advanced immunological diseases, particularly severe respiratory conditions. The company is advancing a monoclonal antibody targeting thymic stromal lymphopoietin (TSLP) into phase 2 development while creating innovative bispecific programs for various immunological disorders. Led by a team of biopharmaceutical executives, Windward Bio aims to address significant unmet medical needs in this field.

Business identity

Operating status
Active
Company type
For Profit
Employee range
11-50 employees
Founded
2024-01-01, Year

Headquarters

Country code
CH
Continent
Europe

Capital profile

Funding and company signals

Funding stage
Early Stage Venture
Funding rounds
1
Total equity funding
$200M
Last funding
Series A / $200M / 2025-01-10
Last equity funding
Series A / $200M
Investors
9
Lead investors
3
Articles
33

Founders and investors

Lead investors

Blue OwlNovo HoldingsOrbiMed

Investors

Blue OwlOmega FundsQiming Venture PartnersRTW InvestmentsSR One